MX2020013322A - Sales de compuestos y cristales de los mismos. - Google Patents

Sales de compuestos y cristales de los mismos.

Info

Publication number
MX2020013322A
MX2020013322A MX2020013322A MX2020013322A MX2020013322A MX 2020013322 A MX2020013322 A MX 2020013322A MX 2020013322 A MX2020013322 A MX 2020013322A MX 2020013322 A MX2020013322 A MX 2020013322A MX 2020013322 A MX2020013322 A MX 2020013322A
Authority
MX
Mexico
Prior art keywords
salts
compound
crystals
compounds
nonae
Prior art date
Application number
MX2020013322A
Other languages
English (en)
Inventor
Ikuo Kushida
Hirofumi Kuroda
Yoko Ito
So Yasui
Jun Niijima
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2020013322A publication Critical patent/MX2020013322A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6587—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having two phosphorus atoms as ring hetero atoms in the same ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona cristales de sales de amonio de (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-difluoro-34,39- bis(sulfanil)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27 -decaaza-34?5,39?5-difosfaoctaciclo[28.6.4.13,36.128,31.04,8.07,1 2.019,24.023,27]dotetrac onta-5,7,9,11,15,19,21,23,25-nonaeno-34,3 9-diona (compuesto (I)), sales de sodio del compuesto (I) o el compuesto (I), que presentan un potencial para usarse como sustancia farmacológica en productos farmacéuticos. (ver Fórmula).
MX2020013322A 2018-08-16 2019-08-14 Sales de compuestos y cristales de los mismos. MX2020013322A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862764774P 2018-08-16 2018-08-16
PCT/JP2019/031951 WO2020036199A1 (en) 2018-08-16 2019-08-14 Salts of compounds and crystals thereof

Publications (1)

Publication Number Publication Date
MX2020013322A true MX2020013322A (es) 2021-02-22

Family

ID=69525441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013322A MX2020013322A (es) 2018-08-16 2019-08-14 Sales de compuestos y cristales de los mismos.

Country Status (12)

Country Link
US (1) US11691990B2 (es)
EP (1) EP3837268A4 (es)
JP (1) JP6767589B1 (es)
KR (1) KR20210045352A (es)
CN (1) CN112041325B (es)
AU (1) AU2019322722A1 (es)
BR (1) BR112021001349A2 (es)
CA (1) CA3099904A1 (es)
MX (1) MX2020013322A (es)
SG (1) SG11202009262VA (es)
TW (1) TWI717804B (es)
WO (1) WO2020036199A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220111028A1 (en) 2020-10-14 2022-04-14 Boehringer Ingelheim International Gmbh Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
CN102199183B (zh) 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
IN2014MN02492A (es) 2012-06-08 2015-07-17 Aduro Biotech
JP6333843B2 (ja) 2012-12-13 2018-05-30 アデュロ バイオテック，インコーポレイテッド 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法
ES2678194T3 (es) 2012-12-19 2018-08-09 Board Of Regents, The University Of Texas System Determinación farmacéutica de una vía de señalización de dinucleótido cíclico de mamífero
WO2014179335A1 (en) 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
PT2996473T (pt) 2013-05-18 2019-11-18 Univ California Composições e métodos para a ativação da sinalização dependente do ''estimulador de genes de interferão''
US20160287623A1 (en) 2013-11-19 2016-10-06 The University Of Chicago Use of sting agonist as cancer treatment
EP3071229A4 (en) 2013-11-22 2017-05-10 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
MX2016015928A (es) * 2014-06-04 2017-03-20 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting.
WO2016079899A1 (ja) 2014-11-20 2016-05-26 国立研究開発法人医薬基盤・健康・栄養研究所 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
US10011630B2 (en) 2014-12-16 2018-07-03 Invivogen Cyclic dinucleotides for cytokine induction
CN112626153A (zh) 2014-12-17 2021-04-09 立博美华基因科技有限责任公司 用cGAMP或cGAsMP治疗癌症的方法
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
AR103894A1 (es) 2015-03-10 2017-06-14 Aduro Biotech Inc Composiciones y métodos para activar la señalización dependiente del estimulador del gen interferón
WO2017011622A1 (en) 2015-07-14 2017-01-19 Spring Bank Pharmaceuticals, Inc. Compounds and compositions that induce rig-i-and other pattern recongnition receptors
US10844051B2 (en) 2015-07-22 2020-11-24 The Royal Institution For The Advancement Of Learning/Mcgill University Substituted oxazoles for the treatment of cancer
GEP20207182B (en) 2015-08-13 2020-11-25 Merck Sharp & Dohme Cyclic di-nucleotide compounds as sting agonists
US9809597B2 (en) 2015-08-20 2017-11-07 The Board Of Trustees Of The Leland Stanford Junior University Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
US20170056448A1 (en) 2015-09-01 2017-03-02 Ifm Therapeutics, Inc Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same
WO2017075477A1 (en) 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
MY194058A (en) 2016-01-11 2022-11-10 Innate Tumor Immunity Inc Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
EP3574018A4 (en) 2017-01-27 2020-10-07 Silverback Therapeutics, Inc. CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE
US20200055883A1 (en) * 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2018198084A1 (en) 2017-04-27 2018-11-01 Lupin Limited Cyclic di-nucleotide compounds with tricyclic nucleobases
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
JP6909061B2 (ja) 2017-06-13 2021-07-28 株式会社三共 遊技機

Also Published As

Publication number Publication date
CN112041325A (zh) 2020-12-04
KR20210045352A (ko) 2021-04-26
US20210198282A1 (en) 2021-07-01
BR112021001349A2 (pt) 2021-04-20
EP3837268A1 (en) 2021-06-23
CA3099904A1 (en) 2020-02-20
US11691990B2 (en) 2023-07-04
TWI717804B (zh) 2021-02-01
EP3837268A4 (en) 2022-04-20
JP2020529967A (ja) 2020-10-15
CN112041325B (zh) 2023-10-24
WO2020036199A1 (en) 2020-02-20
JP6767589B1 (ja) 2020-10-14
AU2019322722A1 (en) 2020-10-15
SG11202009262VA (en) 2020-10-29
TW202015701A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
BR112018014536A2 (pt) derivados de amônio, um processo para sua preparação e composições farmacêuticas contendo os mesmos
CR20200157A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
MX2019004019A (es) Pirrolidinas sustituidas como moduladores cftr.
BR112017027831A2 (pt) derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12017500281B1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
SG11201803699YA (en) 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
BR112018075433A2 (pt) derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os
WO2013061205A8 (en) (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
PH12016500161A1 (en) Thieno[2,3-c]pyrans as cftr modulators
PH12018500605A1 (en) New pyrrolo[2,3-d]pyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201890123A1 (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
EA201790496A1 (ru) Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos
BR112017001803A2 (pt) aril-hidrazidas contendo uma fração de 2-piridona como agentes antibacterianos seletivos
MX2020013322A (es) Sales de compuestos y cristales de los mismos.
MX2020008110A (es) Sal de compuesto de pirazolo[1,5-a]pirimidina y cristales de la misma.
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
BR112015031572A2 (pt) novo processo para a manutenção de uma razão de isômeros de compostos carotenoides
EA201992804A1 (ru) Производные аминогликозида и их применение при лечении генетических заболеваний
EA201600400A1 (ru) Противоопухолевая фармацевтическая композиция, содержащая темозоломид, и способ ее получения